Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541436 | 0.88 | CRHR1 (0.41) | CRHR1RUNX1ALOX5APFEN1GPR3 | |
| SCHEMBL14744212 | 0.77 | ALOX5AP (0.47) | SCN9AALOX5APFEN1CTSAALDH1A1 | |
| SCHEMBL5425106 | 0.74 | CRHR1 (0.51) | CRHR1RUNX1SCN9AALOX5APFEN1 | |
| SCHEMBL6203416 | 0.74 | RUNX1 (0.40) | CRHR1RUNX1SCN9ACTSA | |
| SCHEMBL6203918 | 0.73 | CRHR1 (0.48) | CRHR1RUNX1SCN9AALOX5APFEN1 | |
| SCHEMBL5439627 | 0.73 | CRHR1 (0.56) | CRHR1RUNX1SCN9ACTSA | |
| SCHEMBL4884652 | 0.73 | CRHR1 (0.46) | CRHR1RUNX1SCN9ACTSAGPR3 | |
| SCHEMBL4626672 | 0.73 | CRHR1 (0.48) | CRHR1RUNX1SCN9AGPR3ALDH1A1 | |
| SCHEMBL6286387 | 0.73 | CRHR1 (0.61) | CRHR1RUNX1SCN9AGPR3 | |
| SCHEMBL5409117 | 0.73 | CRHR1 (0.48) | CRHR1RUNX1SCN9ACTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | claimed |
| EP-1500653-A1 | Substituted arylpyrazines | Neurogen Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | claimed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885RUNX1 979/4885SCN9A 3623/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885RUNX1 1026/4885SCN9A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.